ArticleJournal of clinical practice and research2026
FOXM1 Drives Subtype-Specific Dysregulation of Prognostic miRNAs in Breast Cancer Cells.
Article in Journal of clinical practice and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Breast cancer is a heterogeneous disease comprising distinct molecular subtypes, including estrogen receptor-positive (ER+) breast cancer and triple-negative breast cancer (TNBC). MicroRNAs (miRNAs) regulate post-transcriptional gene expression and play important roles in cancer progression by functioning as oncogenic or tumor-suppressive molecules. Forkhead box M1 (FOXM1) is an oncogenic transcription factor that is frequently upregulated in aggressive breast cancers, particularly TNBC, and is associated with proliferation, invasion, metastasis, therapy resistance, and poor prognosis. Materials and Methods: Clinically relevant miRNAs associated with survival in patients with ER+ and ER- breast cancer were identified using publicly available datasets. The expression levels of miR-34a-5p, miR-873-5p, miR-193b-5p, miR-330-5p, miR-10b-5p, miR-155-5p, and miR-484 were evaluated in MDA-MB-231 TNBC cells and MCF-7 ER+ breast cancer cells following FOXM1 knockdown. Results: FOXM1 knockdown was associated with increased expression of several tumor-suppressive miRNAs, including miR-34a-5p, miR-873-5p, miR-193b-5p, miR-330-5p, miR-10b-5p, and miR-484, in MDA-MB-231 cells. In contrast, most of these miRNAs were not markedly altered in MCF-7 cells, except for miR-10b-5p, whose expression decreased following FOXM1 knockdown. miR-155-5p expression remained largely unchanged in both cell lines. Conclusion: Our findings demonstrate that FOXM1 knockdown was associated with differential expression of clinically relevant miRNAs in the two breast cancer cell models examined. These findings suggest that FOXM1-associated alterations in miRNA expression may contribute to the aggressive phenotype of TNBC and warrant further mechanistic investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.